Leerink Swann Boosts Aurinia Pharmaceuticals Inc (AUPH) Price Target to $14.00
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) had its price target hoisted by equities researchers at Leerink Swann from $10.00 to $14.00 in a report issued on Monday. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Leerink Swann’s price objective suggests a potential upside of 129.51% from the company’s current price.
AUPH has been the topic of several other research reports. Vetr downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 target price on the stock. in a research note on Monday, July 31st. Seaport Global Securities reissued a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, October 6th. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Tuesday, August 15th. BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Cantor Fitzgerald set a $14.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $10.15.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down 1.79% during midday trading on Monday, reaching $6.04. The company had a trading volume of 1,679,583 shares. Aurinia Pharmaceuticals has a 12-month low of $2.02 and a 12-month high of $10.54. The company has a 50 day moving average of $6.44 and a 200 day moving average of $6.52. The firm’s market capitalization is $504.25 million.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.10. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. Analysts anticipate that Aurinia Pharmaceuticals will post ($1.01) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/leerink-swann-boosts-aurinia-pharmaceuticals-inc-auph-price-target-to-14-00.html.
A number of large investors have recently added to or reduced their stakes in AUPH. Bank of New York Mellon Corp bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth approximately $595,000. FMR LLC bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth approximately $42,928,000. UBS Group AG increased its stake in Aurinia Pharmaceuticals by 13.6% in the 1st quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock worth $824,000 after acquiring an additional 13,405 shares during the last quarter. Morgan Stanley increased its stake in Aurinia Pharmaceuticals by 11,061.7% in the 1st quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock worth $3,273,000 after acquiring an additional 442,138 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth approximately $776,000. 27.76% of the stock is currently owned by institutional investors and hedge funds.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.